- Home
- ENTA vs COYA Comparison
ENTA vs COYA Comparison
Compare ENTA & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- COYA
- Stock Information
- Founded
- ENTA 1995
- COYA 2020
- Country
- ENTA United States
- COYA United States
- Employees
- ENTA N/A
- COYA N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- COYA Health Care
- Exchange
- ENTA Nasdaq
- COYA Nasdaq
- Market Cap
- ENTA 109.0M
- COYA 98.5M
- IPO Year
- ENTA 2013
- COYA 2022
- Fundamental
- Price
- ENTA $5.09
- COYA $6.27
- Analyst Decision
- ENTA Buy
- COYA Strong Buy
- Analyst Count
- ENTA 4
- COYA 4
- Target Price
- ENTA $17.25
- COYA $16.25
- AVG Volume (30 Days)
- ENTA 503.4K
- COYA 49.8K
- Earning Date
- ENTA 02-18-2025
- COYA 03-18-2025
- Dividend Yield
- ENTA N/A
- COYA N/A
- EPS Growth
- ENTA N/A
- COYA N/A
- EPS
- ENTA N/A
- COYA N/A
- Revenue
- ENTA $67,635,000.00
- COYA $9,554,315.00
- Revenue This Year
- ENTA $8.11
- COYA N/A
- Revenue Next Year
- ENTA N/A
- COYA $87.80
- P/E Ratio
- ENTA N/A
- COYA N/A
- Revenue Growth
- ENTA N/A
- COYA N/A
- 52 Week Low
- ENTA $4.71
- COYA $4.75
- 52 Week High
- ENTA $17.80
- COYA $10.69
- Technical
- Relative Strength Index (RSI)
- ENTA 38.07
- COYA 59.85
- Support Level
- ENTA $4.94
- COYA $5.65
- Resistance Level
- ENTA $5.31
- COYA $6.64
- Average True Range (ATR)
- ENTA 0.32
- COYA 0.33
- MACD
- ENTA 0.11
- COYA 0.08
- Stochastic Oscillator
- ENTA 39.05
- COYA 73.48
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.